Targeting Bone Tumours with 45S5 Bioactive Glass.

Area of Science:

• Biomaterials Science
• Oncology
• Regenerative Medicine

Background:

• Conventional bone tumour treatments like chemotherapy and radiation have severe side effects, leading to poor outcomes and high recurrence rates.
• There is a critical need for novel therapeutic strategies that are effective against bone tumours while minimizing damage to healthy tissues.

Purpose of the Study:

• To investigate the therapeutic potential of 45S5 bioactive glass (BG) for targeting various bone tumours.
• To assess the cytotoxic effects of 45S5-BG on malignant bone tumour cells versus non-malignant bone cells.

Main Methods:

• Assessing the viability of osteosarcoma, chondrosarcoma, giant cell tumour cells, and normal bone cells (osteoblasts, chondrocytes, stromal cells) when exposed to 45S5-BG.
• Evaluating the impact of particle size reduction and sintering on 45S5-BG's cytotoxic effects.
• Utilizing a chicken chorioallantoic membrane assay to assess in vivo anti-tumour efficacy.

Main Results:

• 45S5-BG significantly reduced the viability of osteosarcoma, chondrosarcoma, and giant cell tumour cells.
• Non-malignant bone cells exhibited minimal to no reduction in viability when treated with 45S5-BG.
• Reduced particle size and sintering enhanced the cytotoxic effect of 45S5-BG.
• In vivo studies showed a significant reduction in tumour formation when 45S5-BG was co-transplanted.

Conclusions:

• 45S5 bioactive glass demonstrates significant cytotoxic effects against bone tumour cells with a favourable safety profile for healthy bone cells.
• Optimizing particle size and material structure enhances 45S5-BG's anti-tumour efficacy.
• 45S5-BG shows considerable promise as a novel therapeutic agent for bone tumours, potentially promoting bone regeneration simultaneously.